Taylor Schreiber
Fondatore presso SHATTUCK LABS, INC.
Patrimonio netto: 26 M $ in data 30/04/2024
Posizioni attive di Taylor Schreiber
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SHATTUCK LABS, INC. | Direttore/Membro del Consiglio | 01/01/2016 | - |
| Amministratore Delegato | 01/01/2020 | - | |
| Fondatore | 01/01/2016 | - | |
| Direttore Tecnico/Scientifico/R&S | 01/01/2016 | 01/01/2020 |
Storia della carriera di Taylor Schreiber
Precedenti posizioni note di Taylor Schreiber
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Direttore/Membro del Consiglio | 01/01/2011 | 01/01/2017 |
| SCORPIUS HOLDINGS, INC. | Direttore Tecnico/Scientifico/R&S | 03/03/2014 | 31/12/2016 |
| SCORPIUS HOLDINGS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Taylor Schreiber
| Bucknell University | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SCORPIUS HOLDINGS, INC. | Health Technology |
| SHATTUCK LABS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Pelican Therapeutics, Inc.
Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Health Services |
- Borsa valori
- Insiders
- Taylor Schreiber
- Esperienza
